Anti-CDw17 (Lactosylceramide of LacCer) Monoklonale Antilichaam (Kloon: HO18.3G-6.F5)

CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor) -induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.

Lactosylceramide; LacCer; Î2-D-galactosyl- (1-4) -Î2-D-glucosyl- (1-1') -ceramide; CDw17

Human

Î2-2 Microglobulin associated proteins from a detergent lysate of human PBL

HO18.3G-6.F5

FACS, IF

200 μg/mL of Ab Purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/mL.

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.

Flow Cytometry (1-2ug/million cells) ; Immunofluorescence (1-2ug/ml)

Mouse IgM, kappa